
Eric J. Duncavage, MD
Professor, Pathology & Immunology
Contact
- Email: duncavagee@wustl.edu
- Phone: 314-747-2007
- Fax:
Division: Genomic & Molecular Pathology
Titles
Division Chief, Genomic and Molecular Pathology
Education
Hematopathology Fellow: University of Utah/ARUP lab, Salt Lake City, UT (2009-2010)
Molecular Genetic Pathology Fellow: Washington University, St. Louis, MO (2008-2009)
Resident Physician, Anatomic and Clinical Pathology: Washington University/Barnes-Jewish Hospital, St. Louis, MO (2004-2008)
Medical Degree: University of Tennessee College of Medicine, Memphis, TN (1999-2004)
Cum Laude, Majors in Physics and Chemistry: Vanderbilt University, Nashville, TN (1994-1998)
Tennessee Honors Diploma: Brentwood High School, Brentwood, TN (1990-1994)
Boards
Board Certified in Anatomic and Clinical Pathology
Board Certified in Molecular Pathology
Board Certified in Hematopathology
Board Certified in Clinical Informatics
NY State Certificate of Qualification (Histology and Molecular)
Recognition
Harry Hill Departmental Research Grant, University of Utah, 2009
College of American Pathologists (CAP) Research Training Grant, 2009
Pulmonary Pathology Society Trainee Research Award, USCAP 2009
American Medical Association Resident Research Grant, 2008
CAP Fall Informatics Meeting (APIII) Travel Grant, 2007
CAP Spring Informatics Meeting Travel Grant, 2007
University of Tennessee Alumni Achievement Research Award, 2004
Howard Hughes Medical Institute Predoctoral Fellowship, 2001
NIH Summer Medical Student Research, Fellowship Recipient, 2000
Honorable Mention–Tennessee Biomedical Research Fair, 1998
Research Interests
Dr. Duncavage is a professor in the Department of Pathology and Immunology at WashU Medicine in St. Louis, MO and is a member of the Siteman Cancer Center. He currently serves as the director of Genomic and Molecular Pathology Division and is the former director of the hematopathology section. Dr. Duncavage is board certified in anatomic pathology, clinical pathology, molecular pathology, hematopathology, and clinical informatics. His clinical practice includes sign out of blood, bone marrow, lymph nodes, and molecular diagnostics cases. As the director of molecular oncology, Dr. Duncavage oversees molecular testing in the regulated CAP/CLIA environment including the design and implementation of cutting-edge assays such as MyeloSeq®-HD, a first to market UMI-based NGS assay for the detection of measurable residual disease in myeloid neoplasms, and ChromoSeq®, a first to market comprehensive WGS-based assay for myeloid neoplasms. Dr. Duncavage’s research is focused on understanding the biology of myeloid neoplasms such as MDS and AML and developing better clinical diagnostics using sequencing-based approaches. This work is funded through several NIH and foundation awards and has resulted in multiple high-profile publications.
Selected Publications
Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma
Publication
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Publication
A fully next-generation sequencing-based method of classifying molecular sub-types of endometrial cancer retains prognostic value and expands biomarker targets
Publication
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response: EARLY PHASE STUDIES
Publication
Assistant
